assertion_id	disorder_id	disorder_name	source_file	section	section_index	name	description	category	frequency	diagnostic	context	subtype	role	presence	association	accession	age_range	background	base_model	classification	clinical_significance	consequence	data_type	de_novo_rate	definition_type	duration	effect	expressivity	features	genotype	incubation_days	incubation_years	markers	maximum_value	mean_range	minimum_value	model_format	model_id	model_software	model_type	notes	parent_of_origin_effect	penetrance	percentage	phase	platform	population	publication	repository_url	results	review_notes	sample_count	scope	sequence_length	severity	species	specificity	status	subtype_frequency	title	type	unit	scalar_fields_json	complex_fields_json	raw_json
154	8	Acne Vulgaris	Acne_Vulgaris.yaml	clinical_trials	0	NCT00421993	Multicenter, randomized, double-blind trial comparing adapalene/benzoyl peroxide gel with monotherapies and vehicle in acne vulgaris over 12 weeks.																																						PHASE_III													COMPLETED					"{""description"": ""Multicenter, randomized, double-blind trial comparing adapalene/benzoyl peroxide gel with monotherapies and vehicle in acne vulgaris over 12 weeks."", ""name"": ""NCT00421993"", ""phase"": ""PHASE_III"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Multicenter, randomized, double-blind trial comparing adapalene/benzoyl peroxide gel with monotherapies and vehicle in acne vulgaris over 12 weeks."", ""evidence"": [{""explanation"": ""The trial evaluates a combination topical therapy specifically in participants with acne vulgaris."", ""reference"": ""clinicaltrials:NCT00421993"", ""snippet"": ""This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris."", ""supports"": ""SUPPORT""}], ""name"": ""NCT00421993"", ""phase"": ""PHASE_III"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""comedonal acne"", ""term"": {""id"": ""HP:0040137"", ""label"": ""Comedonal acne""}}, {""preferred_term"": ""erythematous papule"", ""term"": {""id"": ""HP:0030350"", ""label"": ""Erythematous papule""}}, {""preferred_term"": ""pustule"", ""term"": {""id"": ""HP:0200039"", ""label"": ""Pustule""}}]}"
155	8	Acne Vulgaris	Acne_Vulgaris.yaml	clinical_trials	1	NCT02249767	Double-blind, randomized, parallel-group study assessing tretinoin gel bioequivalence in patients with mild acne vulgaris.																																						PHASE_III													COMPLETED					"{""description"": ""Double-blind, randomized, parallel-group study assessing tretinoin gel bioequivalence in patients with mild acne vulgaris."", ""name"": ""NCT02249767"", ""phase"": ""PHASE_III"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Double-blind, randomized, parallel-group study assessing tretinoin gel bioequivalence in patients with mild acne vulgaris."", ""evidence"": [{""explanation"": ""This study explicitly enrolls participants with acne vulgaris and evaluates topical tretinoin treatment."", ""reference"": ""clinicaltrials:NCT02249767"", ""snippet"": ""Normal, healthy male and female children and adults (i.e., ages 12 to 40 years) with at least Grade 2 (i.e., mild severity) acne vulgaris were treated on the full face once daily for 84 days with the Tretinoin Gel 0.05%, Brand (tretinoin) Gel 0.05%, or Gel Vehicle."", ""supports"": ""SUPPORT""}], ""name"": ""NCT02249767"", ""phase"": ""PHASE_III"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""comedonal acne"", ""term"": {""id"": ""HP:0040137"", ""label"": ""Comedonal acne""}}, {""preferred_term"": ""erythematous papule"", ""term"": {""id"": ""HP:0030350"", ""label"": ""Erythematous papule""}}]}"
673	28	Asthma	Asthma.yaml	clinical_trials	0	NCT05813288	A randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of dexpramipexole in participants with severe eosinophilic asthma. The trial evaluated a novel oral treatment approach over 52 weeks in patients with inadequately controlled disease.																																						PHASE_III													COMPLETED					"{""description"": ""A randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of dexpramipexole in participants with severe eosinophilic asthma. The trial evaluated a novel oral treatment approach over 52 weeks in patients with inadequately controlled disease."", ""name"": ""NCT05813288"", ""phase"": ""PHASE_III"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""A randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of dexpramipexole in participants with severe eosinophilic asthma. The trial evaluated a novel oral treatment approach over 52 weeks in patients with inadequately controlled disease."", ""evidence"": [{""explanation"": ""This trial directly evaluates a therapeutic approach for severe eosinophilic asthma, a well-defined phenotype of asthma, and represents current research into treatment options for this severe form of the disease."", ""reference"": ""clinicaltrials:NCT05813288"", ""snippet"": ""The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma."", ""supports"": ""SUPPORT""}], ""name"": ""NCT05813288"", ""phase"": ""PHASE_III"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Wheezing"", ""term"": {""id"": ""HP:0030828"", ""label"": ""Wheezing""}}, {""preferred_term"": ""Breathlessness"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}, {""preferred_term"": ""Chest Tightness"", ""term"": {""id"": ""HP:0031352"", ""label"": ""Chest tightness""}}, {""preferred_term"": ""Coughing"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}]}"
913	39	Bacterial meningitis	Bacterial_meningitis.yaml	clinical_trials	0	NCT02591290	Two-dose MenACWY (Menactra) immunogenicity and safety in healthy Japanese adults.																																						PHASE_IV													COMPLETED					"{""description"": ""Two-dose MenACWY (Menactra) immunogenicity and safety in healthy Japanese adults."", ""name"": ""NCT02591290"", ""phase"": ""PHASE_IV"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Two-dose MenACWY (Menactra) immunogenicity and safety in healthy Japanese adults."", ""evidence"": [{""explanation"": ""MenACWY conjugate vaccine immune response data relevant to bacterial meningitis prevention."", ""reference"": ""clinicaltrials:NCT02591290"", ""snippet"": ""evaluate and describe the immune responses to meningococcal antigens (serogroups A,C, Y and W-135) at 28 days following each vaccination with SP284 vaccine"", ""supports"": ""SUPPORT""}], ""name"": ""NCT02591290"", ""phase"": ""PHASE_IV"", ""status"": ""COMPLETED""}"
914	39	Bacterial meningitis	Bacterial_meningitis.yaml	clinical_trials	1	NCT07062445	Prospective Brazilian pediatric registry capturing acute treatment and long-term outcomes in infectious meningitis.																																						NOT_APPLICABLE													NOT_RECRUITING					"{""description"": ""Prospective Brazilian pediatric registry capturing acute treatment and long-term outcomes in infectious meningitis."", ""name"": ""NCT07062445"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""NOT_RECRUITING""}"	{}	"{""description"": ""Prospective Brazilian pediatric registry capturing acute treatment and long-term outcomes in infectious meningitis."", ""evidence"": [{""explanation"": ""Real-world registry to characterize management and outcomes in pediatric meningitis, informing care protocols."", ""reference"": ""clinicaltrials:NCT07062445"", ""snippet"": ""Prospective, multicenter, observational clinical registry of pediatric patients with acute infectious meningitis"", ""supports"": ""SUPPORT""}], ""name"": ""NCT07062445"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""NOT_RECRUITING""}"
1124	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	0	NCT02958917	Randomized, double-blind, placebo-controlled study evaluating pirfenidone in fibrotic hypersensitivity pneumonitis.																																						PHASE_II													TERMINATED					"{""description"": ""Randomized, double-blind, placebo-controlled study evaluating pirfenidone in fibrotic hypersensitivity pneumonitis."", ""name"": ""NCT02958917"", ""phase"": ""PHASE_II"", ""status"": ""TERMINATED""}"	{}	"{""description"": ""Randomized, double-blind, placebo-controlled study evaluating pirfenidone in fibrotic hypersensitivity pneumonitis."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The registry entry specifies the trial population and disease focus."", ""reference"": ""clinicaltrials:NCT02958917"", ""snippet"": ""Patients are being offered participation in this pirfenidone trial because They have been diagnosed with fibrotic hypersensitivity pneumonitis (FHP), a type of interstitial lung disease (ILD)."", ""supports"": ""SUPPORT""}], ""name"": ""NCT02958917"", ""phase"": ""PHASE_II"", ""status"": ""TERMINATED"", ""target_phenotypes"": [{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}, {""preferred_term"": ""Pulmonary fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}]}"
1125	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	1	NCT02496182	Study evaluating addition of pirfenidone to prednisone and azathioprine in chronic hypersensitivity pneumonitis with pulmonary fibrosis.																																		ClinicalTrials.gov lists Phase 2 and Phase 3 for this study.				PHASE_II													UNKNOWN					"{""description"": ""Study evaluating addition of pirfenidone to prednisone and azathioprine in chronic hypersensitivity pneumonitis with pulmonary fibrosis."", ""name"": ""NCT02496182"", ""notes"": ""ClinicalTrials.gov lists Phase 2 and Phase 3 for this study."", ""phase"": ""PHASE_II"", ""status"": ""UNKNOWN""}"	{}	"{""description"": ""Study evaluating addition of pirfenidone to prednisone and azathioprine in chronic hypersensitivity pneumonitis with pulmonary fibrosis."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The registry summary outlines treatment strategy and target population."", ""reference"": ""clinicaltrials:NCT02496182"", ""snippet"": ""the investigators propose to evaluate the addition of Pirfenidone to the actual treatment with Prednisone and Azathioprine in the treatment of patients with Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis."", ""supports"": ""SUPPORT""}], ""name"": ""NCT02496182"", ""notes"": ""ClinicalTrials.gov lists Phase 2 and Phase 3 for this study."", ""phase"": ""PHASE_II"", ""status"": ""UNKNOWN"", ""target_phenotypes"": [{""preferred_term"": ""Pulmonary fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}, {""preferred_term"": ""Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}]}"
1126	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	2	NCT04844359	Observational study developing and validating a prognostic blood transcriptomic signature in chronic hypersensitivity pneumonitis.																																						NOT_APPLICABLE													ACTIVE_NOT_RECRUITING					"{""description"": ""Observational study developing and validating a prognostic blood transcriptomic signature in chronic hypersensitivity pneumonitis."", ""name"": ""NCT04844359"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""ACTIVE_NOT_RECRUITING""}"	{}	"{""description"": ""Observational study developing and validating a prognostic blood transcriptomic signature in chronic hypersensitivity pneumonitis."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The registry summary describes enrollment and biomarker-focused outcomes."", ""reference"": ""clinicaltrials:NCT04844359"", ""snippet"": ""Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression."", ""supports"": ""SUPPORT""}], ""name"": ""NCT04844359"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""ACTIVE_NOT_RECRUITING"", ""target_phenotypes"": [{""preferred_term"": ""Pulmonary fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}, {""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}]}"
1770	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	clinical_trials	0	NCT05018247	Prospective randomized study comparing early revascularization guided by PET-quantified coronary flow capacity versus optimal medical therapy alone in stable ischemic heart disease.																																						NOT_APPLICABLE																		"{""description"": ""Prospective randomized study comparing early revascularization guided by PET-quantified coronary flow capacity versus optimal medical therapy alone in stable ischemic heart disease."", ""name"": ""NCT05018247"", ""phase"": ""NOT_APPLICABLE""}"	{}	"{""description"": ""Prospective randomized study comparing early revascularization guided by PET-quantified coronary flow capacity versus optimal medical therapy alone in stable ischemic heart disease."", ""evidence"": [{""explanation"": ""The trial directly tests a revascularization strategy for stable ischemic coronary disease, informing interventional management."", ""reference"": ""clinicaltrials:NCT05018247"", ""snippet"": ""To compare the impact of revascularization and Optimal Medical Treatment (OMT) on the extent of severely reduced coronary flow capacity in stable ischemic heart disease."", ""supports"": ""SUPPORT""}], ""name"": ""NCT05018247"", ""phase"": ""NOT_APPLICABLE""}"
2520	111	FICUS syndrome	FICUS_syndrome.yaml	clinical_trials	0	NCT05280691	"Cluster-randomized superiority trial of a multicomponent, nurse-led family support intervention in adult intensive care units.
"																																																								"{""description"": ""Cluster-randomized superiority trial of a multicomponent, nurse-led family support intervention in adult intensive care units.\n"", ""name"": ""NCT05280691""}"	{}	"{""description"": ""Cluster-randomized superiority trial of a multicomponent, nurse-led family support intervention in adult intensive care units.\n"", ""evidence"": [{""explanation"": ""This trial evaluates a family support intervention and targets family outcomes relevant to FICUS."", ""reference"": ""clinicaltrials:NCT05280691"", ""snippet"": ""The primary study endpoint is quality of family care, operationalized as family members' satisfaction with ICU care at discharge."", ""supports"": ""SUPPORT""}], ""name"": ""NCT05280691""}"
2521	111	FICUS syndrome	FICUS_syndrome.yaml	clinical_trials	1	NCT04316767	"Pilot study of a smartphone self-care app delivering cognitive behavioral therapy to reduce psychological symptoms in ICU family members.
"																																																								"{""description"": ""Pilot study of a smartphone self-care app delivering cognitive behavioral therapy to reduce psychological symptoms in ICU family members.\n"", ""name"": ""NCT04316767""}"	{}	"{""description"": ""Pilot study of a smartphone self-care app delivering cognitive behavioral therapy to reduce psychological symptoms in ICU family members.\n"", ""evidence"": [{""explanation"": ""This trial targets psychological symptoms in ICU family members using a CBT-based intervention."", ""reference"": ""clinicaltrials:NCT04316767"", ""snippet"": ""This study will examine the effectiveness of a smartphone self-care app delivering cognitive behavioral therapy in decreasing the psychological symptoms suffered by ICU family members."", ""supports"": ""SUPPORT""}], ""name"": ""NCT04316767""}"
2522	111	FICUS syndrome	FICUS_syndrome.yaml	clinical_trials	2	NCT04839406	"Randomized controlled trial of a systematic follow-up intervention for caregivers of critically ill patients over 12 months.
"																																																								"{""description"": ""Randomized controlled trial of a systematic follow-up intervention for caregivers of critically ill patients over 12 months.\n"", ""name"": ""NCT04839406""}"	{}	"{""description"": ""Randomized controlled trial of a systematic follow-up intervention for caregivers of critically ill patients over 12 months.\n"", ""evidence"": [{""explanation"": ""This trial evaluates an ICU caregiver follow-up intervention aligned with FICUS care needs."", ""reference"": ""clinicaltrials:NCT04839406"", ""snippet"": ""The aim of the project is to test the efficacy of a systematic intervention for individual follow-up of caregivers at the intensive care unit during a 12 month randomized controlled trial."", ""supports"": ""SUPPORT""}], ""name"": ""NCT04839406""}"
2523	111	FICUS syndrome	FICUS_syndrome.yaml	clinical_trials	3	NCT07228299	"Multicenter RCT evaluating chaplain-delivered spiritual care for ICU family surrogates using the SCAI framework.
"																																																								"{""description"": ""Multicenter RCT evaluating chaplain-delivered spiritual care for ICU family surrogates using the SCAI framework.\n"", ""name"": ""NCT07228299""}"	{}	"{""description"": ""Multicenter RCT evaluating chaplain-delivered spiritual care for ICU family surrogates using the SCAI framework.\n"", ""evidence"": [{""explanation"": ""This trial targets psychological and spiritual outcomes in ICU family surrogates, relevant to FICUS."", ""reference"": ""clinicaltrials:NCT07228299"", ""snippet"": ""The overarching goal of our work is to test the effect of high-quality spiritual care for ICU family surrogates on outcomes of psychological and spiritual well-being and medical decision making."", ""supports"": ""SUPPORT""}], ""name"": ""NCT07228299""}"
2644	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	0	NCT04069533	Phase II clinical trial evaluating lentiviral-mediated gene therapy for pediatric patients with Fanconi Anemia subtype A (FA-A). Autologous CD34+ hematopoietic stem cells are transduced ex vivo with a lentiviral vector carrying the FANCA gene, then reinfused with the goal of preventing bone marrow failure.																																						PHASE_II													ACTIVE_NOT_RECRUITING					"{""description"": ""Phase II clinical trial evaluating lentiviral-mediated gene therapy for pediatric patients with Fanconi Anemia subtype A (FA-A). Autologous CD34+ hematopoietic stem cells are transduced ex vivo with a lentiviral vector carrying the FANCA gene, then reinfused with the goal of preventing bone marrow failure."", ""name"": ""NCT04069533"", ""phase"": ""PHASE_II"", ""status"": ""ACTIVE_NOT_RECRUITING""}"	{}	"{""description"": ""Phase II clinical trial evaluating lentiviral-mediated gene therapy for pediatric patients with Fanconi Anemia subtype A (FA-A). Autologous CD34+ hematopoietic stem cells are transduced ex vivo with a lentiviral vector carrying the FANCA gene, then reinfused with the goal of preventing bone marrow failure."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This Phase II gene therapy trial directly addresses the genetic defect in FA-A by correcting FANCA mutations in autologous stem cells, providing evidence for curative cell-based genetic therapy approaches."", ""reference"": ""clinicaltrials:NCT04069533"", ""snippet"": ""This is an open-label Phase II clinical trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for pediatric patients with Fanconi Anemia, subtype A (FA-A). Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene."", ""supports"": ""SUPPORT""}], ""name"": ""NCT04069533"", ""phase"": ""PHASE_II"", ""status"": ""ACTIVE_NOT_RECRUITING"", ""target_phenotypes"": [{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}, {""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}]}"
2645	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	1	NCT00243399	Pilot trial evaluating oxandrolone (an androgen steroid) for treatment of bone marrow aplasia in Fanconi Anemia patients. The study assessed safety and efficacy of androgen therapy to stimulate production of red blood cells and platelets in FA patients with bone marrow failure.																																						PHASE_I													COMPLETED					"{""description"": ""Pilot trial evaluating oxandrolone (an androgen steroid) for treatment of bone marrow aplasia in Fanconi Anemia patients. The study assessed safety and efficacy of androgen therapy to stimulate production of red blood cells and platelets in FA patients with bone marrow failure."", ""name"": ""NCT00243399"", ""phase"": ""PHASE_I"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Pilot trial evaluating oxandrolone (an androgen steroid) for treatment of bone marrow aplasia in Fanconi Anemia patients. The study assessed safety and efficacy of androgen therapy to stimulate production of red blood cells and platelets in FA patients with bone marrow failure."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This Phase I trial evaluates androgen therapy as a bridge treatment for bone marrow failure in FA, providing clinical evidence for hormonal stimulation of hematopoiesis."", ""reference"": ""clinicaltrials:NCT00243399"", ""snippet"": ""The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the production of red blood cells (the cells which carry oxygen in the blood) and platelets (cells that help blood clot)."", ""supports"": ""SUPPORT""}], ""name"": ""NCT00243399"", ""phase"": ""PHASE_I"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}, {""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}]}"
2646	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	2	NCT00630253	Phase I/II study evaluating cyclophosphamide, fludarabine, and antithymocyte globulin conditioning followed by matched sibling donor hematopoietic cell transplantation (HSCT) in patients with Fanconi Anemia. Investigates reduced-intensity conditioning regimens tailored to FA patients' increased chemotherapy sensitivity.																																						PHASE_II													COMPLETED					"{""description"": ""Phase I/II study evaluating cyclophosphamide, fludarabine, and antithymocyte globulin conditioning followed by matched sibling donor hematopoietic cell transplantation (HSCT) in patients with Fanconi Anemia. Investigates reduced-intensity conditioning regimens tailored to FA patients' increased chemotherapy sensitivity."", ""name"": ""NCT00630253"", ""phase"": ""PHASE_II"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Phase I/II study evaluating cyclophosphamide, fludarabine, and antithymocyte globulin conditioning followed by matched sibling donor hematopoietic cell transplantation (HSCT) in patients with Fanconi Anemia. Investigates reduced-intensity conditioning regimens tailored to FA patients' increased chemotherapy sensitivity."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This Phase I/II trial optimizes HSCT conditioning regimens for FA patients, providing clinical evidence for the curative approach to bone marrow failure in Fanconi Anemia."", ""reference"": ""clinicaltrials:NCT00630253"", ""snippet"": ""Giving chemotherapy, such as cyclophosphamide and fludarabine, before a donor stem cell transplant helps to remove the patient's cells to allow for the transplant cells to take and grow. It also helps stop the patient's immune system from rejecting the donor's stem cells."", ""supports"": ""SUPPORT""}], ""name"": ""NCT00630253"", ""phase"": ""PHASE_II"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}, {""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}]}"
4438	188	Long COVID	Long_COVID.yaml	clinical_trials	0	NCT06452082	Retrospective observational study evaluating the effect of vitamin D3 supplementation in reducing the risk of developing Long COVID syndrome after acute COVID-19 illness and in reducing the risk of SARS-CoV-2 infection after vaccination.																																						NOT_APPLICABLE													RECRUITING					"{""description"": ""Retrospective observational study evaluating the effect of vitamin D3 supplementation in reducing the risk of developing Long COVID syndrome after acute COVID-19 illness and in reducing the risk of SARS-CoV-2 infection after vaccination."", ""name"": ""NCT06452082"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""Retrospective observational study evaluating the effect of vitamin D3 supplementation in reducing the risk of developing Long COVID syndrome after acute COVID-19 illness and in reducing the risk of SARS-CoV-2 infection after vaccination."", ""evidence"": [{""explanation"": ""This trial directly investigates interventions to prevent Long COVID development, providing clinical evidence for potential preventive strategies in post-viral syndrome management."", ""reference"": ""clinicaltrials:NCT06452082"", ""snippet"": ""The aim of this observational retrospective study is to evaluate the effect of supplementation with cholecalciferol D3 in reducing the risk of occurence of Long COVID syndrome after acute COVID-19 illness"", ""supports"": ""SUPPORT""}], ""name"": ""NCT06452082"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""RECRUITING"", ""target_phenotypes"": [{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}]}"
4481	189	Ludwig's Angina	Ludwigs_Angina.yaml	clinical_trials	0	NCT01091909	Observational comparison of post-extraction wound healing and surgical complications in type 2 diabetes versus non-diabetic controls, capturing deep neck infections as potential postoperative events.																																						NOT_APPLICABLE																		"{""description"": ""Observational comparison of post-extraction wound healing and surgical complications in type 2 diabetes versus non-diabetic controls, capturing deep neck infections as potential postoperative events."", ""name"": ""NCT01091909"", ""phase"": ""NOT_APPLICABLE""}"	{}	"{""description"": ""Observational comparison of post-extraction wound healing and surgical complications in type 2 diabetes versus non-diabetic controls, capturing deep neck infections as potential postoperative events."", ""evidence"": [{""explanation"": ""Trial monitors surgical complications after dental extractionâ€”relevant because Ludwig's angina is a severe postoperative infection that can arise in this setting."", ""reference"": ""clinicaltrials:NCT01091909"", ""snippet"": ""evaluate clinical healing after dental extraction and the occurrence of surgical complications in patients with type 2 diabetes and compare with non-diabetic patients"", ""supports"": ""SUPPORT""}], ""name"": ""NCT01091909"", ""phase"": ""NOT_APPLICABLE""}"
4523	191	Lyme Disease	Lyme_Disease.yaml	clinical_trials	0	NCT03769194	Randomized, controlled, observer-blind Phase 2 study evaluating immunogenicity and safety of VLA15, a multivalent recombinant OspA-based Lyme borreliosis vaccine candidate in healthy adults aged 18-65 years. Participants received 3 immunizations at monthly intervals.																																						PHASE_II													COMPLETED					"{""description"": ""Randomized, controlled, observer-blind Phase 2 study evaluating immunogenicity and safety of VLA15, a multivalent recombinant OspA-based Lyme borreliosis vaccine candidate in healthy adults aged 18-65 years. Participants received 3 immunizations at monthly intervals."", ""name"": ""NCT03769194"", ""phase"": ""PHASE_II"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Randomized, controlled, observer-blind Phase 2 study evaluating immunogenicity and safety of VLA15, a multivalent recombinant OspA-based Lyme borreliosis vaccine candidate in healthy adults aged 18-65 years. Participants received 3 immunizations at monthly intervals."", ""evidence"": [{""explanation"": ""This Phase 2 trial evaluates VLA15, a preventive vaccine targeting OspA surface protein, offering evidence for active immunization against Lyme borreliosis."", ""reference"": ""clinicaltrials:NCT03769194"", ""snippet"": ""The study was investigated 3 doses of a multivalent OspA (Outer Surface Protein A) based Lyme vaccine (VLA15) in healthy adults aged 18 to 65 years of age. Study participants received 3 immunizations of the vaccine at a monthly interval."", ""supports"": ""SUPPORT""}], ""name"": ""NCT03769194"", ""phase"": ""PHASE_II"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Erythema migrans"", ""term"": {""id"": ""HP:0031180"", ""label"": ""Erythema migrans""}}]}"
4524	191	Lyme Disease	Lyme_Disease.yaml	clinical_trials	1	NCT06785402	Randomized, double-blind, placebo-controlled Phase 1/2 trial evaluating pulse-dosed intravenous ceftriaxone for Post-Treatment Lyme Disease Syndrome (PTLDS). Investigates whether periodic high-dose antibiotic therapy can eliminate persistent Borrelia burgdorferi in patients with persistent symptoms.																																						PHASE_II													RECRUITING					"{""description"": ""Randomized, double-blind, placebo-controlled Phase 1/2 trial evaluating pulse-dosed intravenous ceftriaxone for Post-Treatment Lyme Disease Syndrome (PTLDS). Investigates whether periodic high-dose antibiotic therapy can eliminate persistent Borrelia burgdorferi in patients with persistent symptoms."", ""name"": ""NCT06785402"", ""phase"": ""PHASE_II"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""Randomized, double-blind, placebo-controlled Phase 1/2 trial evaluating pulse-dosed intravenous ceftriaxone for Post-Treatment Lyme Disease Syndrome (PTLDS). Investigates whether periodic high-dose antibiotic therapy can eliminate persistent Borrelia burgdorferi in patients with persistent symptoms."", ""evidence"": [{""explanation"": ""This Phase 1/2 trial directly addresses post-treatment Lyme disease syndrome with a novel pulse-dosing regimen, providing clinical evidence for managing antibiotic-refractory cases."", ""reference"": ""clinicaltrials:NCT06785402"", ""snippet"": ""Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS). The goal of this study is to investigate if giving Ceftriaxone every 5 days for about 6 weeks kills the organism that produces persistent Lyme infection."", ""supports"": ""SUPPORT""}], ""name"": ""NCT06785402"", ""phase"": ""PHASE_II"", ""status"": ""RECRUITING"", ""target_phenotypes"": [{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}, {""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}]}"
4525	191	Lyme Disease	Lyme_Disease.yaml	clinical_trials	2	NCT03584919	European prospective clinical trial comparing doxycycline and cefuroxime axetil for treatment of erythema migrans in adult patients. Participants were evaluated at baseline, 14 days, and 2, 6, and 12 months post-enrollment to assess treatment efficacy and long-term outcomes.																																						NOT_APPLICABLE													COMPLETED					"{""description"": ""European prospective clinical trial comparing doxycycline and cefuroxime axetil for treatment of erythema migrans in adult patients. Participants were evaluated at baseline, 14 days, and 2, 6, and 12 months post-enrollment to assess treatment efficacy and long-term outcomes."", ""name"": ""NCT03584919"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""European prospective clinical trial comparing doxycycline and cefuroxime axetil for treatment of erythema migrans in adult patients. Participants were evaluated at baseline, 14 days, and 2, 6, and 12 months post-enrollment to assess treatment efficacy and long-term outcomes."", ""evidence"": [{""explanation"": ""This comparative trial evaluates two oral antibiotics for early Lyme disease, providing evidence for treatment options and long-term symptom outcomes in erythema migrans patients."", ""reference"": ""clinicaltrials:NCT03584919"", ""snippet"": ""A European, prospective clinical trial in which doxycycline and cefuroxime axetil were compared in the treatment of adult patients with erythema migrans included a control group to address this question. Evaluations of patients were conducted at baseline, 14 days and 2, 6, and 12 months after enrollment."", ""supports"": ""SUPPORT""}], ""name"": ""NCT03584919"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Erythema migrans"", ""term"": {""id"": ""HP:0031180"", ""label"": ""Erythema migrans""}}]}"
4868	206	Meckel Syndrome	Meckel_Syndrome.yaml	clinical_trials	0	NCT01401998	Observational translational resource for hepato/renal fibrocystic diseases, including Meckel-Gruber syndrome, collecting clinical data and biospecimens.																																						NOT_APPLICABLE																		"{""description"": ""Observational translational resource for hepato/renal fibrocystic diseases, including Meckel-Gruber syndrome, collecting clinical data and biospecimens."", ""name"": ""NCT01401998"", ""phase"": ""NOT_APPLICABLE""}"	{}	"{""description"": ""Observational translational resource for hepato/renal fibrocystic diseases, including Meckel-Gruber syndrome, collecting clinical data and biospecimens."", ""evidence"": [{""explanation"": ""The trial encompasses Meckel-Gruber syndrome within a hepato-renal fibrocystic disease registry."", ""reference"": ""clinicaltrials:NCT01401998"", ""snippet"": ""Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and other diseases with common features (Joubert syndrome, Bardet Biedl syndrome, Meckel-Gruber syndrome, congenital hepatic fibrosis (CHF), Caroli syndrome (CS), polycystic liver disease, oro-facial-digital syndrome, nephronophithisis (NPHP), and glomerulocystic Kidney Disease)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The trial is structured as a translational resource and registry."", ""reference"": ""clinicaltrials:NCT01401998"", ""snippet"": ""This study aims to build a registry of a clinical database (medical health information), a mutational database (genetic information) and an educational resource about HRFD"", ""supports"": ""SUPPORT""}], ""name"": ""NCT01401998"", ""phase"": ""NOT_APPLICABLE""}"
5078	214	Migraine	Migraine.yaml	clinical_trials	0	NCT07040813	A randomized placebo-controlled double-blind trial investigating the efficacy of onabotulinumtoxin A (Botox) added to CGRP monoclonal antibody therapy for chronic migraine prevention over 12 weeks. The study evaluates dual therapy versus CGRP monoclonal antibody monotherapy in reducing monthly migraine days.																																						PHASE_III													RECRUITING					"{""description"": ""A randomized placebo-controlled double-blind trial investigating the efficacy of onabotulinumtoxin A (Botox) added to CGRP monoclonal antibody therapy for chronic migraine prevention over 12 weeks. The study evaluates dual therapy versus CGRP monoclonal antibody monotherapy in reducing monthly migraine days."", ""name"": ""NCT07040813"", ""phase"": ""PHASE_III"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""A randomized placebo-controlled double-blind trial investigating the efficacy of onabotulinumtoxin A (Botox) added to CGRP monoclonal antibody therapy for chronic migraine prevention over 12 weeks. The study evaluates dual therapy versus CGRP monoclonal antibody monotherapy in reducing monthly migraine days."", ""evidence"": [{""explanation"": ""This Phase III trial directly evaluates a combination approach targeting two major migraine pathways (CGRP and acetylcholine) for chronic migraine prevention."", ""reference"": ""clinicaltrials:NCT07040813"", ""snippet"": ""The study will evaluate the efficacy of onabotulinumtoxin A when added to CGRP monoclonal antibody therapy in chronic migraine prevention. Adverse events and change in disease activity will be monitored."", ""supports"": ""SUPPORT""}], ""name"": ""NCT07040813"", ""phase"": ""PHASE_III"", ""status"": ""RECRUITING"", ""target_phenotypes"": [{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}, {""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}]}"
5079	214	Migraine	Migraine.yaml	clinical_trials	1	NCT06241313	Randomized, double-blind, placebo-controlled, multiple-attack study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and consistency of effect with an open-label extension phase.																																						PHASE_III													RECRUITING					"{""description"": ""Randomized, double-blind, placebo-controlled, multiple-attack study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and consistency of effect with an open-label extension phase."", ""name"": ""NCT06241313"", ""phase"": ""PHASE_III"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""Randomized, double-blind, placebo-controlled, multiple-attack study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and consistency of effect with an open-label extension phase."", ""evidence"": [{""explanation"": ""This Phase III trial evaluates atogepant, a CGRP antagonist, for acute migraine treatment, providing clinical evidence for transitioning this preventive agent to acute attack management."", ""reference"": ""clinicaltrials:NCT06241313"", ""snippet"": ""The main goal of the study is to see if atogepant is effective, safe, and well-tolerated in treating migraine attacks quickly. Atogepant is a medicine currently approved for the preventive treatment of migraine in adults and has been shown to be effective and well tolerated when taken daily to prevent migraine attacks."", ""supports"": ""SUPPORT""}], ""name"": ""NCT06241313"", ""phase"": ""PHASE_III"", ""status"": ""RECRUITING"", ""target_phenotypes"": [{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}, {""preferred_term"": ""Photophobia"", ""term"": {""id"": ""HP:0000613"", ""label"": ""Photophobia""}}, {""preferred_term"": ""Phonophobia"", ""term"": {""id"": ""HP:0002183"", ""label"": ""Phonophobia""}}]}"
5080	214	Migraine	Migraine.yaml	clinical_trials	2	NCT07061847	Study evaluating bilateral middle meningeal artery (MMA) lidocaine infusion as a novel interventional approach for chronic debilitating migraines. Investigates localized anesthesia targeting the pain-sensitive meningeal tissues implicated in migraine pathophysiology.																																						PHASE_II													RECRUITING					"{""description"": ""Study evaluating bilateral middle meningeal artery (MMA) lidocaine infusion as a novel interventional approach for chronic debilitating migraines. Investigates localized anesthesia targeting the pain-sensitive meningeal tissues implicated in migraine pathophysiology."", ""name"": ""NCT07061847"", ""phase"": ""PHASE_II"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""Study evaluating bilateral middle meningeal artery (MMA) lidocaine infusion as a novel interventional approach for chronic debilitating migraines. Investigates localized anesthesia targeting the pain-sensitive meningeal tissues implicated in migraine pathophysiology."", ""evidence"": [{""explanation"": ""This Phase II trial investigates a novel interventional procedure targeting meningeal pain pathways in chronic migraine, providing clinical evidence for direct vascular intervention approaches."", ""reference"": ""clinicaltrials:NCT07061847"", ""snippet"": ""The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine intensity, frequency, and duration."", ""supports"": ""SUPPORT""}], ""name"": ""NCT07061847"", ""phase"": ""PHASE_II"", ""status"": ""RECRUITING"", ""target_phenotypes"": [{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}]}"
6421	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	clinical_trials	0	NCT06037577	Double-blind, randomized, placebo-controlled study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of single escalating subcutaneous doses of CM-101, an anti-fibrotic agent developed for PSC.																																						PHASE_I																		"{""description"": ""Double-blind, randomized, placebo-controlled study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of single escalating subcutaneous doses of CM-101, an anti-fibrotic agent developed for PSC."", ""name"": ""NCT06037577"", ""phase"": ""PHASE_I""}"	{}	"{""description"": ""Double-blind, randomized, placebo-controlled study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of single escalating subcutaneous doses of CM-101, an anti-fibrotic agent developed for PSC."", ""evidence"": [{""explanation"": ""This Phase I study characterizes CM-101, a candidate therapy for PSC and related fibrotic diseases, establishing early human safety data."", ""reference"": ""clinicaltrials:NCT06037577"", ""snippet"": ""CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). In this current study, the IP is tested in healthy male volunteers."", ""supports"": ""SUPPORT""}], ""name"": ""NCT06037577"", ""phase"": ""PHASE_I""}"
6465	276	Proteus syndrome	Proteus_syndrome.yaml	clinical_trials	0	NCT04316546	Multi-cohort Phase 2 dose-escalation study of miransertib (MK-7075) in Proteus syndrome.																																						PHASE_II													RECRUITING					"{""description"": ""Multi-cohort Phase 2 dose-escalation study of miransertib (MK-7075) in Proteus syndrome."", ""name"": ""NCT04316546"", ""phase"": ""PHASE_II"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""Multi-cohort Phase 2 dose-escalation study of miransertib (MK-7075) in Proteus syndrome."", ""evidence"": [{""explanation"": ""The trial objective confirms evaluation of miransertib for Proteus syndrome."", ""reference"": ""clinicaltrials:NCT04316546"", ""snippet"": ""To learn if miransertib is a safe and effective treatment for Proteus syndrome."", ""supports"": ""SUPPORT""}], ""name"": ""NCT04316546"", ""phase"": ""PHASE_II"", ""status"": ""RECRUITING""}"
6466	276	Proteus syndrome	Proteus_syndrome.yaml	clinical_trials	1	NCT02594215	Dose-finding study of MK-7075 (miransertib) in children and adults with Proteus syndrome.																																						PHASE_I													COMPLETED					"{""description"": ""Dose-finding study of MK-7075 (miransertib) in children and adults with Proteus syndrome."", ""name"": ""NCT02594215"", ""phase"": ""PHASE_I"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Dose-finding study of MK-7075 (miransertib) in children and adults with Proteus syndrome."", ""evidence"": [{""explanation"": ""The trial objective defines dose-finding and safety assessment in Proteus syndrome."", ""reference"": ""clinicaltrials:NCT02594215"", ""snippet"": ""To determine the safety, tolerability, and recommended dose of MK-7075 in people with PS."", ""supports"": ""SUPPORT""}], ""name"": ""NCT02594215"", ""phase"": ""PHASE_I"", ""status"": ""COMPLETED""}"
6467	276	Proteus syndrome	Proteus_syndrome.yaml	clinical_trials	2	NCT03094832	Phase 1/2 open-label study of oral miransertib (MK-7075) in PROS and Proteus syndrome (MOSAIC).																																						PHASE_I													TERMINATED					"{""description"": ""Phase 1/2 open-label study of oral miransertib (MK-7075) in PROS and Proteus syndrome (MOSAIC)."", ""name"": ""NCT03094832"", ""phase"": ""PHASE_I"", ""status"": ""TERMINATED""}"	{}	"{""description"": ""Phase 1/2 open-label study of oral miransertib (MK-7075) in PROS and Proteus syndrome (MOSAIC)."", ""evidence"": [{""explanation"": ""The trial summary describes the Phase 1/2 MOSAIC study including Proteus syndrome."", ""reference"": ""clinicaltrials:NCT03094832"", ""snippet"": ""This is an open label, Phase 1/2 study of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) (MOSAIC)."", ""supports"": ""SUPPORT""}], ""name"": ""NCT03094832"", ""phase"": ""PHASE_I"", ""status"": ""TERMINATED""}"
6468	276	Proteus syndrome	Proteus_syndrome.yaml	clinical_trials	3	NCT04980872	Extension study evaluating safety/tolerability of oral miransertib in PROS or Proteus syndrome.																																						PHASE_II													ACTIVE_NOT_RECRUITING					"{""description"": ""Extension study evaluating safety/tolerability of oral miransertib in PROS or Proteus syndrome."", ""name"": ""NCT04980872"", ""phase"": ""PHASE_II"", ""status"": ""ACTIVE_NOT_RECRUITING""}"	{}	"{""description"": ""Extension study evaluating safety/tolerability of oral miransertib in PROS or Proteus syndrome."", ""evidence"": [{""explanation"": ""The study summary states the safety/tolerability focus for PROS or Proteus syndrome participants."", ""reference"": ""clinicaltrials:NCT04980872"", ""snippet"": ""This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS)."", ""supports"": ""SUPPORT""}], ""name"": ""NCT04980872"", ""phase"": ""PHASE_II"", ""status"": ""ACTIVE_NOT_RECRUITING""}"
6469	276	Proteus syndrome	Proteus_syndrome.yaml	clinical_trials	4	NCT03317366	Expanded access for ARQ 092 (miransertib) in overgrowth diseases or vascular anomalies with PI3K/AKT alterations.																																						NOT_APPLICABLE													UNKNOWN					"{""description"": ""Expanded access for ARQ 092 (miransertib) in overgrowth diseases or vascular anomalies with PI3K/AKT alterations."", ""name"": ""NCT03317366"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""UNKNOWN""}"	{}	"{""description"": ""Expanded access for ARQ 092 (miransertib) in overgrowth diseases or vascular anomalies with PI3K/AKT alterations."", ""evidence"": [{""explanation"": ""The summary describes expanded access for PI3K/AKT-pathway overgrowth disorders including Proteus syndrome."", ""reference"": ""clinicaltrials:NCT03317366"", ""snippet"": ""ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be available for patients who are ineligible for an ongoing ARQ 092 clinical trial or have other considerations that prevent access to ARQ 092 through an existing clinical trial."", ""supports"": ""SUPPORT""}], ""name"": ""NCT03317366"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""UNKNOWN""}"
6470	276	Proteus syndrome	Proteus_syndrome.yaml	clinical_trials	5	NCT00001403	Natural history study of Proteus syndrome and related congenital overgrowth disorders.																																						NOT_APPLICABLE													RECRUITING					"{""description"": ""Natural history study of Proteus syndrome and related congenital overgrowth disorders."", ""name"": ""NCT00001403"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""Natural history study of Proteus syndrome and related congenital overgrowth disorders."", ""evidence"": [{""explanation"": ""The study description states a natural history focus on Proteus syndrome."", ""reference"": ""clinicaltrials:NCT00001403"", ""snippet"": ""This study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patients with Proteus syndrome, whose physical features are characterized by overgrowth, benign tumors of fatty tissue or blood vessels, asymmetric arms or legs, and large feet with very thick soles."", ""supports"": ""SUPPORT""}], ""name"": ""NCT00001403"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""RECRUITING""}"
6665	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	clinical_trials	0	NCT02488109	Randomized trial comparing lower calorie versus higher calorie refeeding in hospitalized adolescents with anorexia nervosa.																																						NOT_APPLICABLE													COMPLETED					"{""description"": ""Randomized trial comparing lower calorie versus higher calorie refeeding in hospitalized adolescents with anorexia nervosa."", ""name"": ""NCT02488109"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Randomized trial comparing lower calorie versus higher calorie refeeding in hospitalized adolescents with anorexia nervosa."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This trial evaluates refeeding strategies relevant to preventing refeeding complications."", ""reference"": ""clinicaltrials:NCT02488109"", ""snippet"": ""The purpose of this study is to compare the efficacy, safety, and cost-effectiveness of lower calorie refeeding versus higher calorie refeeding in hospitalized adolescents with anorexia nervosa."", ""supports"": ""SUPPORT""}], ""name"": ""NCT02488109"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""COMPLETED""}"
6666	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	clinical_trials	1	NCT04966858	Trial comparing individualized caloric refeeding to higher calorie refeeding in hospitalized patients with atypical anorexia nervosa.																																						NOT_APPLICABLE													ENROLLING_BY_INVITATION					"{""description"": ""Trial comparing individualized caloric refeeding to higher calorie refeeding in hospitalized patients with atypical anorexia nervosa."", ""name"": ""NCT04966858"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""ENROLLING_BY_INVITATION""}"	{}	"{""description"": ""Trial comparing individualized caloric refeeding to higher calorie refeeding in hospitalized patients with atypical anorexia nervosa."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This trial directly compares refeeding protocols in a high-risk malnourished population."", ""reference"": ""clinicaltrials:NCT04966858"", ""snippet"": ""The primary purpose of the trial is to compare the efficacy and safety of Individualized Caloric Refeeding (ICR) to the new standard of care, Higher Calorie Refeeding (HCR), in hospitalized patients with atypical anorexia nervosa (AAN), and clinical remission over one year of follow-up."", ""supports"": ""SUPPORT""}], ""name"": ""NCT04966858"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""ENROLLING_BY_INVITATION""}"
6844	293	Salla Disease	Salla_Disease.yaml	clinical_trials	0	NCT03047369	"The Myelin Disorders Biorepository Project (MDBP) and Global Leukodystrophy Initiative Clinical Trials Network is an international research initiative that collects and analyzes clinical data and biological samples from leukodystrophy patients worldwide. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals. Researchers use these materials to uncover new genetic etiologies, develop biomarkers for future clinical trials, and better understand disease natural history.
"																																																			RECRUITING					"{""description"": ""The Myelin Disorders Biorepository Project (MDBP) and Global Leukodystrophy Initiative Clinical Trials Network is an international research initiative that collects and analyzes clinical data and biological samples from leukodystrophy patients worldwide. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals. Researchers use these materials to uncover new genetic etiologies, develop biomarkers for future clinical trials, and better understand disease natural history.\n"", ""name"": ""NCT03047369"", ""status"": ""RECRUITING""}"	{}	"{""description"": ""The Myelin Disorders Biorepository Project (MDBP) and Global Leukodystrophy Initiative Clinical Trials Network is an international research initiative that collects and analyzes clinical data and biological samples from leukodystrophy patients worldwide. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals. Researchers use these materials to uncover new genetic etiologies, develop biomarkers for future clinical trials, and better understand disease natural history.\n"", ""evidence"": [{""explanation"": ""MDBP is an active biorepository network that includes Salla disease as a condition of interest for myelin disorder research."", ""reference"": ""clinicaltrials:NCT03047369"", ""snippet"": ""The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects."", ""supports"": ""SUPPORT""}], ""name"": ""NCT03047369"", ""status"": ""RECRUITING""}"
6950	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	clinical_trials	0	NCT00891527	Pilot study using bevacizumab (Avastin) and imatinib (Gleevec) to treat progression of multivessel intraluminal pulmonary vein stenosis in children. Pulmonary vein stenosis is a major postoperative complication of scimitar syndrome repair.																																						PHASE_II													COMPLETED					"{""description"": ""Pilot study using bevacizumab (Avastin) and imatinib (Gleevec) to treat progression of multivessel intraluminal pulmonary vein stenosis in children. Pulmonary vein stenosis is a major postoperative complication of scimitar syndrome repair."", ""name"": ""NCT00891527"", ""phase"": ""PHASE_II"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Pilot study using bevacizumab (Avastin) and imatinib (Gleevec) to treat progression of multivessel intraluminal pulmonary vein stenosis in children. Pulmonary vein stenosis is a major postoperative complication of scimitar syndrome repair."", ""evidence"": [{""explanation"": ""Phase I/II trial targeting pulmonary vein stenosis in children, directly relevant to the postoperative complication of scimitar syndrome repair."", ""reference"": ""clinicaltrials:NCT00891527"", ""snippet"": ""The objective of this study is to conduct a pilot study using biologic agents Avastin and Gleevec to treat progression of multivessel intraluminal pulmonary vein stenosis in children."", ""supports"": ""SUPPORT""}], ""name"": ""NCT00891527"", ""phase"": ""PHASE_II"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}]}"
6951	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	clinical_trials	1	NCT01548950	Combined preoperative and postoperative sildenafil and bosentan treatment for congenital heart disease associated with pulmonary arterial hypertension. Tests whether PAH drug therapy reduces perioperative mortality and residual PAH in children undergoing cardiac repair for left-to-right shunts.																																						NOT_APPLICABLE													COMPLETED					"{""description"": ""Combined preoperative and postoperative sildenafil and bosentan treatment for congenital heart disease associated with pulmonary arterial hypertension. Tests whether PAH drug therapy reduces perioperative mortality and residual PAH in children undergoing cardiac repair for left-to-right shunts."", ""name"": ""NCT01548950"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Combined preoperative and postoperative sildenafil and bosentan treatment for congenital heart disease associated with pulmonary arterial hypertension. Tests whether PAH drug therapy reduces perioperative mortality and residual PAH in children undergoing cardiac repair for left-to-right shunts."", ""evidence"": [{""explanation"": ""Trial of perioperative PAH pharmacotherapy in CHD with left-to-right shunts, applicable to scimitar syndrome patients with significant pulmonary hypertension undergoing surgical repair."", ""reference"": ""clinicaltrials:NCT01548950"", ""snippet"": ""The purpose of this study is to test the hypothesis that treating PAH-CHD patients preoperatively with PAH drugs and keeping them on treatment for six months after surgery reduces the risk of immediate postoperative death and the risk of residual PAH at six months following operation to <10%."", ""supports"": ""SUPPORT""}], ""name"": ""NCT01548950"", ""phase"": ""NOT_APPLICABLE"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}]}"
6952	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	clinical_trials	2	NCT03431649	Randomized comparison of beraprost sodium versus sildenafil for treatment of pulmonary hypertension in children with left-to-right shunt congenital heart defects. Directly relevant to pharmacological management of PAH in scimitar syndrome.																																						PHASE_IV													COMPLETED					"{""description"": ""Randomized comparison of beraprost sodium versus sildenafil for treatment of pulmonary hypertension in children with left-to-right shunt congenital heart defects. Directly relevant to pharmacological management of PAH in scimitar syndrome."", ""name"": ""NCT03431649"", ""phase"": ""PHASE_IV"", ""status"": ""COMPLETED""}"	{}	"{""description"": ""Randomized comparison of beraprost sodium versus sildenafil for treatment of pulmonary hypertension in children with left-to-right shunt congenital heart defects. Directly relevant to pharmacological management of PAH in scimitar syndrome."", ""evidence"": [{""explanation"": ""Phase IV trial comparing two PAH medications in pediatric left-to-right shunt CHD, directly applicable to pharmacological management of scimitar syndrome-associated PAH."", ""reference"": ""clinicaltrials:NCT03431649"", ""snippet"": ""To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt."", ""supports"": ""SUPPORT""}], ""name"": ""NCT03431649"", ""phase"": ""PHASE_IV"", ""status"": ""COMPLETED"", ""target_phenotypes"": [{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}]}"
7566	331	Tuberculosis	Tuberculosis.yaml	clinical_trials	0	NCT03568383	Open-label randomized prophylaxis study comparing delamanid versus isoniazid for preventing active tuberculosis among high-risk household contacts of adults with multidrug-resistant TB over 96 weeks of follow-up.																																						PHASE_III																		"{""description"": ""Open-label randomized prophylaxis study comparing delamanid versus isoniazid for preventing active tuberculosis among high-risk household contacts of adults with multidrug-resistant TB over 96 weeks of follow-up."", ""name"": ""NCT03568383"", ""phase"": ""PHASE_III""}"	{}	"{""description"": ""Open-label randomized prophylaxis study comparing delamanid versus isoniazid for preventing active tuberculosis among high-risk household contacts of adults with multidrug-resistant TB over 96 weeks of follow-up."", ""evidence"": [{""explanation"": ""This trial evaluates delamanid as preventive therapy for household contacts of MDR-TB patients, directly relevant to tuberculosis control strategies."", ""reference"": ""clinicaltrials:NCT03568383"", ""snippet"": ""The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases)."", ""supports"": ""SUPPORT""}], ""name"": ""NCT03568383"", ""phase"": ""PHASE_III""}"
